Tharimmune (NASDAQ:THAR) Stock Rating Lowered by Wall Street Zen

Tharimmune (NASDAQ:THAR) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tharimmune in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $17.00.

Tharimmune Stock Down 0.3%

Shares of THAR opened at $2.87 on Friday. Tharimmune has a 12-month low of $0.95 and a 12-month high of $9.08. The firm has a market capitalization of $16.93 million, a price-to-earnings ratio of -0.47 and a beta of 1.41. The stock’s 50-day moving average price is $3.33 and its 200 day moving average price is $2.10.

Tharimmune (NASDAQ:THAR) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.06).

Hedge Funds Weigh In On Tharimmune

A hedge fund recently bought a new stake in Tharimmune stock. Franklin Resources Inc. purchased a new stake in Tharimmune, Inc. (NASDAQ:THAR) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 45,000 shares of the company’s stock, valued at approximately $88,000. Franklin Resources Inc. owned approximately 1.07% of Tharimmune at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.16% of the company’s stock.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).